I believe Cyclin-Dependent Kinase 9 (CDK9) inhibitors are one modality that will bring us a step closer to that future. By targeting the fundamental processes that enable cancer cell survival ...

WILMINGTON, DE — Prelude Therapeutics (Nasdaq: PRLD) presented encouraging interim results from its Phase 1 trial of PRT2527, an investigational CDK9 inhibitor, at the 66th American Society of ...

The closing of the Offering is expected to occur on or about January 29, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be ...

orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors. “KB-0742 represents a promising new approach to treating cancers that are ...

The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared ...

SELLAS Life Sciences Group, Inc.’s SLS share price has dipped by 17.02%, which has investors questioning if this is right ...

The company is also advancing SLS009, a small molecule CDK9 inhibitor with promising potential in treating acute myeloid leukemia. The press release includes forward-looking statements regarding ...